IsoRay expansion ahead of schedule
IsoRay Medical (Richland, Washington), the manufacturer and distributor of Proxcelan (Cesium-131) seeds used in brachytherapy for the treatment of prostate cancer, plans to transfer production in September to expanded production facilities 75 days ahead of schedule. The facility is located at Energy Northwest's applied process engineering laboratory in Richland.
The 15,340-square-foot expansion brings the total production space to about 20,000 square feet, consolidating IsoRay's current U.S. operations into a single location. It will allow IsoRay to more than double its seed production capacity to about 100,000 seeds per month, said IsoRay's executive VP of operations David Swanberg.
According to Swanberg, the finished seeds will be handled, assayed and packaged in the facility's class 10,000 clean room environment. Proxcelan seeds will be offered in a full range of custom, pre-loaded configurations for IsoRay customers based in ambulatory surgical centers, hospitals and major medical universities across the U.S.
IsoRay makes the Proxcelan (Cesium-131) brachytherapy seed, used to treat prostate and other cancers.